Participants in this study have a genetic mutation, specifically in the coagulation (blood clotting) Factor 9 gene that causes severe or moderately severe hemophilia B. This study is researching an experimental gene insertion therapy (the adding of a gene into your DNA) called REGV131-LNP1265, also called the "study drug". Gene insertion therapy aims to teach the body how to produce clotting factor long-term, without the need for factor replacement therapy.
The main aim of this study is to find a safe and well-tolerated dose of the study drug by checking the side effects that may happen from taking it, both in the near term and over time.
The study is looking at several other research questions including:
* How much study drug is in the blood at different times * Whether the body makes antibodies against parts of the study drug, which could make the drug less effective or could lead to side effects. Antibodies are proteins produced by the body's immune system in response to a foreign substance * Whether the body makes antibodies against the clotting factor replacement therapy * How often factor replacement therapy is needed, both on a regular basis for prevention of bleeding, and as needed to treat bleeding events (and it if changes after taking study drug) * Whether there is a difference in 2 different methods for measuring Factor 9 activity in the blood
Confirmed diagnosis of severe or moderately severe hemophilia B with medical history of FIX functional activity (≤2% or <0.02 IU/mL) or documented genotype known to produce severe hemophilia B
Currently taking FIX prophylaxis and previous experience with FIX therapy, as defined in the protocol
Participation in the lead-in period of this interventional study OR a separate lead-in study (R0000-HEMB-2187 [NCT05568459]) for at least 6 months for ABR data while taking FIX prophylaxis, as defined in the protocol
History of FIX inhibitor (clinical or laboratory-based assessment) on 2 or more occasions
Bethesda inhibitor titer greater than the Upper Limit of Normal (ULN) at screening
Detectable pre-existing antibodies to the AAV8 capsid; as measured by Enzyme-Linked ImmunoSorbent Assay (ELISA) at prescreening (or final lead-in visit, if applicable)
Any significant underlying liver disease such as: cholestatic liver disease, liver cirrhosis, portal hypertension, splenomegaly, hepatic encephalopathy
Sequential
REGV131
DrugAdministered per the protocol before LNP1265
LNP1265
DrugAdministered per the protocol following REGV131
7
Treatment groupsSee each treatment group below.
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Part 1, 2B, and 2C
Severity of TEAEs
Part 1, 2B, and 2C
Coagulation Factor IX (FIX) functional activity measured using the chromogenic substrate assay
Part 1
Change in FIX functional activity in plasma, measured using the chromogenic substrate assay
Part 2A, 2B, and 2C
Change in FIX functional activity in plasma measured using the chromogenic substrate assay
Part 1
ABR following sustained FIX functional activity among participants receiving the RDE
LTFU Period for Part 1, 2A, 2B, and 2C
FIX functional activity in plasma over time during the study period using the chromogenic substrate assay
LTFU Period for Part 1, 2A, 2B, and 2C
Annualized treated Bleeding Rate (tABR) following sustained FIX functional activity, among participants receiving the RDE
Part 1, 2A, 2B, and 2C
Click on the lead sponsor to view all of their trials.
Regeneron Pharmaceuticals
Lead sponsor
Intellia Therapeutics
Collaborator